Evotec
Tommaso Carlucci is a Senior Scientist in Translational Microbiology at Evotec, a role held since August 2018, after previously serving as a Research Scientist in the same field. Prior to this, Tommaso conducted neuroimmunology research as a Postdoctoral Research Fellow at Università degli Studi di Verona from November 2014 to July 2018. Tommaso completed a PhD in Inflammation, Immunity and Cancer at Università degli Studi di Verona between 2012 and 2014, following a degree in Bioinformatics and Medical Biotechnology specializing in Neuroinflammation. Earlier educational accomplishments include a degree in Biomedical Laboratory Techniques from Università Politecnica delle Marche and a high school diploma from Liceo Scientifico E. Medi in Senigallia.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.